|Videos|October 11, 2016
Atopic Dermatitis: Cost and Value
Advertisement
Episodes in this series
Panelists Peter L. Salgo, MD; Cheryl Allen, BS Pharm, MBA; Jonathan Silverberg, MD, PhD, MPH; Ed Pezalla, MD, MPH; and Jeffrey D. Dunn, PharmD, MBA, provide insight on balancing the cost and benefit of treatments for atopic dermatitis.
Advertisement
Related to this article
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
4
Finerenone Receives FDA Approval for Treatment of Adults With CKD Associated With T1D
5